ARK Investment Management Predicts Significant Growth for Exact Sciences\n\nARK Investment Management, a renowned investment firm specializing in disruptive technologies, has recently made a compelling case for biotech company Exact Sciences (NASDAQ:EXAS). According to ARK’s founder Cathie Wood, Exact Sciences has tremendous potential for growth and could see its stock price soar by 115% to $139 by 2027.\n\nExact Sciences is a leader in cancer detection and treatment, with its Cologuard screening test being the industry standard for colon cancer. The company has also developed a next-generation test, Cologuard 2.0, which has shown even more accurate results in clinical trials. Additionally, Exact Sciences has created a multi-cancer early detection (MCED) test, which can screen for multiple types of cancer with a single, minimally invasive blood test.\n\nRecent policy changes by insurers and Medicare have also provided a potential catalyst for Exact Sciences. These changes allow for follow-up colonoscopies at no cost to the patient after a positive Cologuard test, which could encourage more patients to take the test. Furthermore, Exact Sciences has seen strong financial results in the third quarter, with revenue increasing by 20% year over year and the company turning a profit.\n\nARK’s valuation model for Exact Sciences outlines three potential outcomes by 2027, with the base case suggesting a 115% increase in stock price. This is significantly higher than the expected 40% return of the S&P 500 during the same period.\n\n Exact Sciences has shown promising developments in cancer detection and treatment, and recent policy changes and financial results bode well for the company’s future.